Not Yet Recruiting
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
NCT05911061
- Conditions
- COVID-19, Coronaviridae Infections, Coronavirus Infections, +9 more
- Locations
-
Not specified